Eli Lilly posts robust second-quarter sales results

Share this article:

Eli Lilly posted strong second-quarter sales results yesterday, despite a 19% net income drop due to charges and other items.

Lilly reported that its second-quarter sales rose to $4.63 billion from $3.87 billion.

Second-quarter highlights included:

*Sales of the Indianapolis drugmaker's best-selling product, the antipsychotic Zyprexa, which totaled $1.2 billion, a 9% increase compared with the second-quarter of 2006. U.S. sales of Zyprexa rose 4%, to $563.5 million. Zyprexa sales in international markets were up 14%, to $649.4 million.

*Sales of antidepressant Cymbalta, which generated $519.5 million, an increase of 67%. U.S. sales of Cymbalta were up 70% to $457.6 million. Sales outside the U.S. were $61.9 million, an increase of 53%.

* Sales of chemotherapy Gemzar, which totaled $395.6 million, an increase of 15%. Sales in the US were up 11% to $165.8 million, while sales outside the US rose 19%, to $229.8 million.

*Sales of osteoporosis treatment Evista, which totaled $278 million. US sales of Evista increased 1%, to $176.9 million. Sales outside the U.S. increased 1% to $101.1 million.

*Sales of Cialis for the second-quarter, which generated $293.1 million. Worldwide sales of Cialis grew 26%. US sales of Cialis were $110.2 million, a 17% increase.

*Worldwide sales of insulin Humulin, which increased 10% to $242.8 million.

*Sales of lung cancer treatment Alimta generated sales of $207.1 million, an increase of 35%. US sales of Alimta increased 22% to $107.4 million, while sales outside the U.S. increased 53%, to $99.7 million.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...